<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Cell Mol Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Cell. Mol. Med</journal-id>
      <journal-id journal-id-type="publisher-id">jcmm</journal-id>
      <journal-title-group>
        <journal-title>Journal of Cellular and Molecular Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1582-1838</issn>
      <issn pub-type="epub">1582-4934</issn>
      <publisher>
        <publisher-name>John Wiley &amp; Sons, Ltd</publisher-name>
        <publisher-loc>Chichester, UK</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24628986</article-id>
      <article-id pub-id-type="pmc">4508147</article-id>
      <article-id pub-id-type="doi">10.1111/jcmm.12252</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>Defeng</given-names>
          </name>
          <xref ref-type="aff" rid="au1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Qian</surname>
            <given-names>Liren</given-names>
          </name>
          <xref ref-type="aff" rid="au1">a</xref>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shen</surname>
            <given-names>Jianliang</given-names>
          </name>
          <xref ref-type="aff" rid="au1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Xiaopeng</given-names>
          </name>
          <xref ref-type="aff" rid="au1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mei</surname>
            <given-names>Ke</given-names>
          </name>
          <xref ref-type="aff" rid="au2">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cen</surname>
            <given-names>Jian</given-names>
          </name>
          <xref ref-type="aff" rid="au1">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Yaming</given-names>
          </name>
          <xref ref-type="aff" rid="au3">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Congyong</given-names>
          </name>
          <xref ref-type="aff" rid="au4">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>Yuanyuan</given-names>
          </name>
          <xref ref-type="aff" rid="au1">a</xref>
        </contrib>
        <aff id="au1">
          <label>a</label>
          <institution>Department of Hematology, Navy General Hospital of PLA</institution>
          <addr-line>Beijing, China</addr-line>
        </aff>
        <aff id="au2">
          <label>b</label>
          <institution>Department of Radiology, Shanghai Jiaotong University Affiliated First People's Hospital</institution>
          <addr-line>Shanghai, China</addr-line>
        </aff>
        <aff id="au3">
          <label>c</label>
          <institution>Department of Neurosurgery, Navy General Hospital of PLA</institution>
          <addr-line>Beijing, China</addr-line>
        </aff>
        <aff id="au4">
          <label>d</label>
          <institution>Department of Gastroenterology, Cadre Ward, Navy General Hospital of PLA</institution>
          <addr-line>Beijing, China</addr-line>
        </aff>
      </contrib-group>
      <author-notes>
        <corresp id="cor1">
* Correspondence to: Liren QIAN, Department of Hematology, Navy General Hospital of PLA, Fucheng Road, Beijing 100048, China., Tel./Fax: +86 10 66957676, E-mail: <email>qlr2007@126.com</email></corresp>
        <fn id="fn1">
          <p>Liren Qian and Defeng Zhao contribute equally to the paper.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <month>6</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>3</month>
        <year>2014</year>
      </pub-date>
      <volume>18</volume>
      <issue>6</issue>
      <fpage>1081</fpage>
      <lpage>1086</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>11</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>21</day>
          <month>1</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley &amp; Sons Ltd and Foundation for Cellular and Molecular Medicine.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <license-p>This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The overall response rates and long-term survival of primary central nervous system lymphoma (PCNSL) are still significantly inferior to the results achieved in similar subtypes of extranodal non-Hodgkin's lymphoma. It is clearly necessary to investigate new therapeutic methods on PCNSL. We encountered three patients histologically documented PCNSL as diffuse large B-cell lymphoma (DLBCL). They were treated with R-IDARAM which comprised rituximab, idarubicin, dexamethasone, cytarabine and methotrexate. Patient 1 received stereotactic brachytherapy (SBT) prior to chemotherapy performed with iodine-125 seeds (cumulative therapeutic dose 50&#xA0;Gy). After six cycles of R-IDARAM at 3-weekly intervals, radiotherapy was applied at a dosage of 2000&#x2013;4000 cGy in conventional schedule (180 or 200 cGy/day) to whole brain or spinal cord in all patients. Complete remission (CR) was achieved after first two cycles of R-IDARAM in all patients. All three patients remained in CR at the time of this report with a median duration of follow-up of 23&#xA0;months (ranging from 13 to 41&#xA0;months). Three patients have been alive for 41, 13, 16&#xA0;months respectively until now. The patient with the longest survival time was the one given SBT prior to chemotherapy. This study suggests that R-IDARAM combining with radiotherapy maybe a high effective regimen in PCNSL patients especially those with primary central nervous system DLBCL. A comprehensive treatment combining internal radiotherapy by SBT, modified R-IDARAM and followed reduced external radiotherapy may be a new treatment concept for PCNSL with higher efficiency and lower toxicity.</p>
      </abstract>
      <kwd-group>
        <kwd>R-IDARAM</kwd>
        <kwd>primary central nervous system lymphoma</kwd>
        <kwd>diffuse large B-cell lymphoma</kwd>
        <kwd>stereotactic brachytherapy</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Primary central nervous system lymphoma (PCNSL) is a rare subtype of non-Hodgkin's lymphoma (NHL) that is confined to the brain, eyes, leptomeninges or spinal cord in the absence of extracerebral tumour manifestation and metastases [<xref rid="b1" ref-type="bibr">1</xref>]. Primary central nervous system lymphoma accounts for 3.3% of all brain tumours [<xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref>]. Diffuse large B-cell lymphoma (DLBCL) accounts for about 90% of PCNSL according to the World Health Organization (WHO) Lymphoma Classification. The remainders include Burkitt's lymphoma, T-cell-rich B-cell lymphoma, peripheral T-cell lymphoma and rarely &#x2018;low-grade&#x2019; B-cell lymphoma [<xref rid="b3" ref-type="bibr">3</xref>,<xref rid="b4" ref-type="bibr">4</xref>]. Overall incidence of PCNSL in the immunocompetent population has been increasing during the last several decades, and it is one of the few malignant primary brain tumours that is sensitive to both chemotherapy and radiotherapy treatment.</p>
      <p>Because of methotrexate (MTX)-based combination chemotherapy, survival has improved over the last three decades. The addition of MTX-based combination chemotherapy to whole brain radiotherapy has improved disease-free survival and overall survival significantly [<xref rid="b5" ref-type="bibr">5</xref>&#x2013;<xref rid="b7" ref-type="bibr">7</xref>]. But the overall response rates and long-term survival are still significantly inferior to the results achieved in similar subtypes of extranodal NHL [<xref rid="b8" ref-type="bibr">8</xref>]. Long-term treatment-related neurological toxicity remains a major problem. It is clearly necessary to investigate new therapeutic methods on PCNSL.</p>
      <p>Stereotactic brachytherapy (SBT) with implantation of iodine-125 seeds is a kind of well-developed internal radiotherapy method which has been successfully used in certain CNS tumours with many benefits such as few side effects, continuously killing tumour cells, <italic>etc</italic>., but it has not been used in CNS lymphoma previously [<xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b10" ref-type="bibr">10</xref>]. Stereotactic brachytherapy with implantation of iridium-192 sources was applied on PCNSL as Apuzzo <italic>et&#xA0;al</italic>. described [<xref rid="b11" ref-type="bibr">11</xref>] in 1980s, but it has not been widely used. To our knowledge, SBT with implantation of iodine-125 seeds was given prior to chemotherapy to one of the patients for the first time in this study.</p>
      <p>R-IDARAM chemotherapy regimen (rituximab, idarubicin, dexamethasone, cytosine arabinoside, MTX, intrathechal MTX and cytosine arabinoside) was applied in very few patients until now [<xref rid="b2" ref-type="bibr">2</xref>]. In this study, we modified the regimens by reducing MTX to 2&#xA0;g/m<sup>2</sup> to reduce its toxicity and rituximab was used independently on day 1 because of the long time of infusion. Herein, we report one PCNSL patient received a comprehensive treatment with SBT, modified R-IDARAM, and followed reduced external radiotherapy and the other two patients presenting with mass lesions in the CNS, received specifically CNS targeted chemotherapy in combination with consolidated external radiotherapy.</p>
    </sec>
    <sec>
      <title>Methods and patients</title>
      <p>This study was performed at departments of Haematology and Neurosurgery in Navy General Hospital in China between August 2010 and November 2013. We have encountered three patients with histologically documented CNSL. Informed consent was provided by each patient. Patient 1 and patient 2 were newly diagnosed as primary central nervous system DLBCL by stereotactic biopsy in the department of Neurosurgery as previously described [<xref rid="b12" ref-type="bibr">12</xref>,<xref rid="b13" ref-type="bibr">13</xref>]. Patient 2 was newly diagnosed as primary central nervous system DLBCL by CT-guided aspiration biopsy. The modified R-IDARAM chemotherapy regimen was applied to all patients. This regimen comprised of rituximab 375&#xA0;mg/m<sup>2</sup> (day 1); idarubicin 10&#xA0;mg/m<sup>2</sup> (day 2 and 3); dexamethasone 100&#xA0;mg/m<sup>2</sup> (12&#xA0;hrs infusion in day 2, 3 and 4); cytarabine 1&#xA0;g/m<sup>2</sup> (1&#xA0;hr infusion in day 2 and 3); MTX 2&#xA0;g/m<sup>2</sup> (6&#xA0;hrs infusion in day 4 with folinic acid rescue) and cytarabine 70&#xA0;mg plus 12&#xA0;mg MTX <italic>via</italic> intrathecal route in day 2 and 9. Colony-stimulating factor (150&#xA0;&#x3BC;g/m<sup>2</sup>) was also started at the seventh day of chemotherapy. Chemotherapy cycles were given at 3-weekly intervals. After course 6, external radiotherapy was applied to whole brain or spinal cord at a dosage of 2000&#x2013;4000 cGy in conventional schedule (180 cGy or 200 cGy per day). However, in patient 1, SBT was applied when biopsy was being carried out by using iodine-125 seeds (cumulative therapeutic dose 50 Gy) prior to chemotherapy as previously described [<xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b14" ref-type="bibr">14</xref>,<xref rid="b15" ref-type="bibr">15</xref>]. Chemotherapy was performed after SBT.</p>
      <p>Response to chemotherapy and the toxicity were evaluated every two courses of chemotherapy and after external RT according to Response Criteria by Lauren E. Abrey <italic>et&#xA0;al</italic>. [<xref rid="b8" ref-type="bibr">8</xref>] ([Table<xref ref-type="table" rid="tbl1">1</xref>). Patients who achieved complete remission (CR) were followed up every 3&#xA0;months in the first year. At follow-up visits, complete neurological and ophthalmological examination, and MRIs were performed. The toxicity of the regimen was graded by objective measures according to the Common Toxicity Criteria [<xref rid="b16" ref-type="bibr">16</xref>].</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <p>Response criteria for primary central nervous system lymphoma <xref rid="b8" ref-type="bibr">8</xref></p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Response</th>
              <th align="left" rowspan="1" colspan="1">Brain imaging</th>
              <th align="left" rowspan="1" colspan="1">Corticosteroid dose</th>
              <th align="left" rowspan="1" colspan="1">Eye examination</th>
              <th align="left" rowspan="1" colspan="1">CSF cytology</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">CR</td>
              <td align="left" rowspan="1" colspan="1">No contrast enhancement</td>
              <td align="left" rowspan="1" colspan="1">None</td>
              <td align="left" rowspan="1" colspan="1">Normal</td>
              <td align="left" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td align="left" rowspan="2" colspan="1">CRu</td>
              <td align="left" rowspan="1" colspan="1">No contrast enhancement</td>
              <td align="left" rowspan="1" colspan="1">Any</td>
              <td align="left" rowspan="1" colspan="1">Normal</td>
              <td align="left" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Minimal abnormality</td>
              <td align="left" rowspan="1" colspan="1">Any</td>
              <td align="left" rowspan="1" colspan="1">Minor RPE abnormality</td>
              <td align="left" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td align="left" rowspan="2" colspan="1">PR</td>
              <td align="left" rowspan="1" colspan="1">50% decrease in enhancing tumour</td>
              <td align="left" rowspan="1" colspan="1">Irrelevant</td>
              <td align="left" rowspan="1" colspan="1">Minor RPE abnormality or normal</td>
              <td align="left" rowspan="1" colspan="1">Negative</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">No contrast enhancement</td>
              <td align="left" rowspan="1" colspan="1">Irrelevant</td>
              <td align="left" rowspan="1" colspan="1">Decrease in vitreous cells or retinal infiltrate</td>
              <td align="left" rowspan="1" colspan="1">Persistent or suspicious</td>
            </tr>
            <tr>
              <td align="left" rowspan="2" colspan="1">PD</td>
              <td align="left" rowspan="1" colspan="1">25% increase in lesion</td>
              <td align="left" rowspan="1" colspan="1">Irrelevant</td>
              <td align="left" rowspan="1" colspan="1">Recurrent or new ocular disease</td>
              <td align="left" rowspan="1" colspan="1">Recurrent or positive</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Any new site of disease: CNS or systemic</td>
              <td align="left" colspan="3" rowspan="1"/>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="tf1-1">
            <p>CR, complete response;</p>
          </fn>
          <fn id="tf1-2">
            <p>CRu, unconfirmed complete response;</p>
          </fn>
          <fn id="tf1-3">
            <p>RPE, retinal pigment epithelium;</p>
          </fn>
          <fn id="tf1-4">
            <p>PR, partial response;</p>
          </fn>
          <fn id="tf1-5">
            <p>PD, progressive disease.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <sec>
        <title>Patient 1</title>
        <p>A 57-year-old man was admitted to the hospital with half a month history of right-side limb inflexible and fatigue. A mild reduced muscle strength on right-side limb was detected (Level IV) by clinical examination. MR imaging studies showed a mass lesion on the left basal ganglia. A tumour biopsy was obtained by stereotactic operation. Stereotactic brachytherapy was performed at the same time. Histopathological examination showed DLBCL. Immunohistochemical examination revealed CD20(+++), LCA(+++), CD79(++), MuM-1(++), BCL-2(+), CD39(&#x2212;), CD45RO(&#x2212;), BCL-6(&#x2212;), CD10(&#x2212;), GFAP(&#x2212;), SYN(&#x2212;), S-100(&#x2212;), CD68(&#x2212;), NeuN(&#x2212;), CD34(&#x2212;), EMA(&#x2212;), Olig-2(&#x2212;), NF(&#x2212;), WT-1(&#x2212;) and Ki-67 index 90%.</p>
      </sec>
      <sec>
        <title>Patient 2</title>
        <p>A 49-year-old woman was admitted to the hospital with a month history of irrelevant answers and slow responsive. Clinical examination was negative. MR imaging studies showed multiple mass lesions on bilateral lobi temporalis and the left frontal lobe. A tumour biopsy was obtained by stereotactic operation. Histopathological examination showed DLBCL. Immunohistochemical examination revealed LCA(+++), CD20(+++), PAX5(+++), CD3(&#x2212;), CD5(&#x2212;), FOXP1(+++), BCL2(++),BCL6(++), MuM-1(++), CD10(&#x2212;), ALK(&#x2212;), TDT(&#x2212;), OLig2(&#x2212;), GFAP(&#x2212;),CD138(&#x2212;), CD30(&#x2212;) and Ki-67 index &gt;90%.</p>
      </sec>
      <sec>
        <title>Patient 3</title>
        <p>A 53-year-old man was admitted to the hospital with half a month history of dysuresia and fatigue. Right-side hemiplegic paralysis and reduced muscle strengths were detected on the left upper limb muscle (Level IV) and the left lower limb muscle strength (Level I) by clinical examination. MR imaging studies showed a mass lesion on the lumbar spinal canal. A tumour biopsy was obtained <italic>via</italic> CT-guided aspiration biopsy. Histopathological examination showed DLBCL. Immunohistochemical examination revealed LCA(+++), Vimentin(+++), AE1/AE3(&#x2212;), CD20(+++), CD79a(++), CD3(&#x2212;), TdT(&#x2212;), Bcl-6(+), CD10(+), MuM-1(&#x2212;), CD138(&#x2212;), Bcl-2(&#x2212;), CD43(+), HHV-8(&#x2212;) and Ki-67 index &gt;95%.</p>
      </sec>
    </sec>
    <sec sec-type="results">
      <title>Results</title>
      <p>The mean age of three patients was 53 (range 49&#x2013;57). Clinical and radiological features of patients are summarized in Table<xref ref-type="table" rid="tbl2">2</xref>. The time between the onset of the symptoms and admission to the hospital were 0.5&#x2013;1&#xA0;month. In all patients HIV, HBV and anti-HCV antibodies were negative. In all patients, the tumours were diagnosed as DLBCL according to the revised European-American classification of lymphoid neoplasms (REAL) and to the WHO Classification of neoplastic diseases of the haematopoietic lymphoid tissues [<xref rid="b17" ref-type="bibr">17</xref>].</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <p>Clinical and radiological features of patients with PCNSL</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Case No.</th>
              <th align="left" rowspan="1" colspan="1">1</th>
              <th align="left" rowspan="1" colspan="1">2</th>
              <th align="left" rowspan="1" colspan="1">3</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Age</td>
              <td align="left" rowspan="1" colspan="1">57</td>
              <td align="left" rowspan="1" colspan="1">49</td>
              <td align="left" rowspan="1" colspan="1">53</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Sex</td>
              <td align="left" rowspan="1" colspan="1">Male</td>
              <td align="left" rowspan="1" colspan="1">Female</td>
              <td align="left" rowspan="1" colspan="1">Male</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">B symptoms</td>
              <td align="left" rowspan="1" colspan="1">&#x2212;</td>
              <td align="left" rowspan="1" colspan="1">&#x2212;</td>
              <td align="left" rowspan="1" colspan="1">+</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Other symptoms</td>
              <td align="left" rowspan="1" colspan="1">Right-side limb inflexible, fatigue</td>
              <td align="left" rowspan="1" colspan="1">Irrelevant answers, slow responsive, right-side hemiplegic paralysis</td>
              <td align="left" rowspan="1" colspan="1">Dysuresia, fatigue</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Lymphadenopathy</td>
              <td align="left" rowspan="1" colspan="1">&#x2212;</td>
              <td align="left" rowspan="1" colspan="1">&#x2212;</td>
              <td align="left" rowspan="1" colspan="1">&#x2212;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Bone marrow involvement</td>
              <td align="left" rowspan="1" colspan="1">&#x2212;</td>
              <td align="left" rowspan="1" colspan="1">&#x2212;</td>
              <td align="left" rowspan="1" colspan="1">&#x2212;</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Number of mass lesion</td>
              <td align="left" rowspan="1" colspan="1">Single</td>
              <td align="left" rowspan="1" colspan="1">Multiple</td>
              <td align="left" rowspan="1" colspan="1">Single</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Size (cm)</td>
              <td align="left" rowspan="1" colspan="1">3.5&#xA0;&#xD7;&#xA0;4.5</td>
              <td align="left" rowspan="1" colspan="1">3.8&#xA0;&#xD7;&#xA0;5.1 (maximal)</td>
              <td align="left" rowspan="1" colspan="1">1.3&#xA0;&#xD7;&#xA0;3.5</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">LDH</td>
              <td align="left" rowspan="1" colspan="1">102&#xA0;U/l (Normal)</td>
              <td align="left" rowspan="1" colspan="1">151&#xA0;U/l (Normal)</td>
              <td align="left" rowspan="1" colspan="1">106&#xA0;U/l (Normal)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">KPS</td>
              <td align="left" rowspan="1" colspan="1">50</td>
              <td align="left" rowspan="1" colspan="1">60</td>
              <td align="left" rowspan="1" colspan="1">10</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">IPI</td>
              <td align="left" rowspan="1" colspan="1">3</td>
              <td align="left" rowspan="1" colspan="1">2</td>
              <td align="left" rowspan="1" colspan="1">2</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Response</td>
              <td align="left" rowspan="1" colspan="1">CR</td>
              <td align="left" rowspan="1" colspan="1">CR</td>
              <td align="left" rowspan="1" colspan="1">CR</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Survival (months)</td>
              <td align="left" rowspan="1" colspan="1">41</td>
              <td align="left" rowspan="1" colspan="1">13</td>
              <td align="left" rowspan="1" colspan="1">16</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="tf2-1">
            <p>B symptoms: fever, night sweats and weight loss;</p>
          </fn>
          <fn id="tf2-2">
            <p>LDH: lactate dehydrogenase;</p>
          </fn>
          <fn id="tf2-3">
            <p>KPS: Karnofsky performance score;</p>
          </fn>
          <fn id="tf2-4">
            <p>PCNSL: primary central nervous system lymphoma.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
      <p>In all three patients, CR was achieved after two chemotherapy cycles of R-IDARAM (Figs <xref ref-type="fig" rid="fig03">3</xref>). All three patients remained in CR at the time of this report with a median duration of follow-up of 23&#xA0;months (range 13&#x2013;41&#xA0;months). Three patients have been alive for 41, 13, 16&#xA0;months respectively until now. The patient with the longest survival time was the one given SBT prior to chemotherapy.</p>
      <fig id="fig01" position="float">
        <label>Figure 1</label>
        <caption>
          <p>In Patient 1, MR scan shows a mass lesion on the left basal ganglia (A). After stereotactic brachytherapy, chemotherapy and reduced external RT, CT/PET-CT/MR images show the lesion disappeared (B).</p>
        </caption>
        <graphic xlink:href="jcmm0018-1081-f1"/>
      </fig>
      <fig id="fig02" position="float">
        <label>Figure 2</label>
        <caption>
          <p>In Patient 2, MR scan shows multiple mass lesions on bilateral lobi temporalis and the left frontal lobe (A). After two cycles of chemotherapy, MR images show the lesion disappeared (B).</p>
        </caption>
        <graphic xlink:href="jcmm0018-1081-f2"/>
      </fig>
      <fig id="fig03" position="float">
        <label>Figure 3</label>
        <caption>
          <p>In Patient 3, MR scan shows a mass lesion on the lumbar spinal canal (A). After two cycles of chemotherapy, MR images show the lesion disappeared (B).</p>
        </caption>
        <graphic xlink:href="jcmm0018-1081-f3"/>
      </fig>
      <p>Observed acute chemotherapy-related toxicities were shown in Table<xref ref-type="table" rid="tbl3">3</xref>. All these medical problems were resolved with supportive medical treatments. Toxicity depending on RT was not seen except dermal and mucosal toxicities during RT until now. All these symptoms disappeared with symptomatic treatments.</p>
      <table-wrap id="tbl3" position="float">
        <label>Table 3</label>
        <caption>
          <p>Acute chemotherapy-related toxicity</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Toxicity/grade (ECOG criteria)</th>
              <th align="left" rowspan="1" colspan="1">Patient 1</th>
              <th align="left" rowspan="1" colspan="1">Patient 2</th>
              <th align="left" rowspan="1" colspan="1">Patient 3</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">Hematologic</td>
              <td align="left" rowspan="1" colspan="1">3</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Infection</td>
              <td align="left" rowspan="1" colspan="1">2</td>
              <td align="left" rowspan="1" colspan="1">1</td>
              <td align="left" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Fever in absence of infection</td>
              <td align="left" rowspan="1" colspan="1">2</td>
              <td align="left" rowspan="1" colspan="1">1</td>
              <td align="left" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Mucosal</td>
              <td align="left" rowspan="1" colspan="1">1</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Nausea and vomiting</td>
              <td align="left" rowspan="1" colspan="1">2</td>
              <td align="left" rowspan="1" colspan="1">1</td>
              <td align="left" rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Renal/bladder</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Neurologic</td>
              <td align="left" rowspan="1" colspan="1">1</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Cardiac</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Liver</td>
              <td align="left" rowspan="1" colspan="1">2</td>
              <td align="left" rowspan="1" colspan="1">1</td>
              <td align="left" rowspan="1" colspan="1">0</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">Gastrointestinal</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">0</td>
              <td align="left" rowspan="1" colspan="1">0</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Although regimens such as R-MPV (rituximab, MTX, vincristine, procarbazine), MBVP (MTX, teniposide, carmustine and methylprednisolone), CHOD/BVAM (cyclophosphamide, doxorubicin, vincristine, dexamethasone/vincristine, cytosine arabinoside, MTX) <italic>etc</italic>. have shown promise [<xref rid="b18" ref-type="bibr">18</xref>&#x2013;<xref rid="b20" ref-type="bibr">20</xref>], there is a clear need to continue to try to optimize chemotherapy regimens and to explore new comprehensive treatments on PCNSL because of lower 2-year overall and progression-free survival than the results achieved in similar subtypes of extranodal NHL, limited doses of chemotherapy deliverable into the CNS, high rates of neurotoxicity, <italic>etc</italic>. [<xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b18" ref-type="bibr">18</xref>]. To our knowledge, combining SBT, chemotherapy and reduced external radiotherapy as a novel multimodal treatment concept was firstly used in PCNSL in this study which showed great efficiency and safety.</p>
      <p>Chemotherapy was the first-line treatment for PCNSL if patients are sufficiently fit. The IDARAM regimen was found to be effective in seven patients with PCNSL by Moreton <italic>et&#xA0;al</italic>. [<xref rid="b2" ref-type="bibr">2</xref>]. and was modified by Yilmaz <italic>et&#xA0;al</italic>. to R-IDARAM in three patients with PCNSL [<xref rid="b21" ref-type="bibr">21</xref>]. The most important problem of drug deliver is the blood&#x2013;brain barrier. To achieve therapeutic concentrations of MTX in the brain, high doses are required (<italic>i.e</italic>. at least 1.5&#xA0;g/m<sup>2</sup>). Cytarabine can penetrate to the brain parenchyma and cerebrospinal fluid (CSF) ara-c concentrations ranged from 1.2&#xA0;&#x3BC;M at 4&#xA0;g to 4.1&#xA0;&#x3BC;M at 18&#xA0;g as Donehower <italic>et&#xA0;al</italic>. reported [<xref rid="b22" ref-type="bibr">22</xref>]. Most anthracyclines probably do not cross the blood&#x2013;brain barrier. But as the major circulating metabolite of idarubicin, idarubicinol is present in the CSF following intravenous administration idarubicin at sustained levels [<xref rid="b23" ref-type="bibr">23</xref>]. Dexamethasone will also penetrate the blood&#x2013;brain barrier [<xref rid="b24" ref-type="bibr">24</xref>]. Rituximab has been detected in the CSF at concentration at most 0.1% after intravenous administration in patients with CNS lymphoma [<xref rid="b25" ref-type="bibr">25</xref>]. Rituximab transport to the CSF may occur <italic>via</italic> leaking across areas of blood&#x2013;brain barrier breakdown in the lymphoma and/or macromolecular vesicular transport of the antibody across an intact blood&#x2013;brain barrier [<xref rid="b26" ref-type="bibr">26</xref>]. The R-IDARAM was still not widely used in PCNSL with good efficiency and tolerable toxicity. In this study, we modified the regimens by reducing MTX to 2&#xA0;g/m<sup>2</sup> to reduce its toxicity without reducing its efficiency.</p>
      <p>In this study, consolidation radiotherapy is performed in all three patients after chemotherapy. There is evidence that the addition of radiotherapy can achieve modest improvement in disease-free and overall survival [<xref rid="b27" ref-type="bibr">27</xref>]. The role of consolidation radiotherapy is controversial because of limited long-term efficiency [<xref rid="b28" ref-type="bibr">28</xref>] and neurotoxicity, which presents as dementia, ataxia and urinary incontinence, and is associated with MRI evidence of leucoencephalopathy after a delay of several years [<xref rid="b29" ref-type="bibr">29</xref>,<xref rid="b30" ref-type="bibr">30</xref>]. The risk of delayed neurotoxicity is generally thought to be the greatest in elderly patients [<xref rid="b6" ref-type="bibr">6</xref>].</p>
      <p>Although in these three patients, neurotoxicity of radiotherapy was not seen currently because of the short-term follow-up, it is not assured whether neurotoxicity will appear in the following years. In this study, patient 1 has survived for 41&#xA0;months with disease-free until now who was performed SBT before chemotherapy and reduced external RT after chemotherapy.</p>
      <p>Stereotactic brachytherapy with implantation of iodine-125 seeds represents a safe and effective local treatment option for certain brain tumours [<xref rid="b31" ref-type="bibr">31</xref>&#x2013;<xref rid="b33" ref-type="bibr">33</xref>]. Histological evaluation within the same operative session, precise treatment of the tumour, maximal sparing of surrounding healthy tissue, minimal rate of long-term complications and preservation of the whole therapeutic spectrumin case of tumour progression (<italic>e.g</italic>. reimplantation, external radiotherapy) are described hallmarks of SBT [<xref rid="b32" ref-type="bibr">32</xref>&#x2013;<xref rid="b34" ref-type="bibr">34</xref>].</p>
      <p>In this study, we assessed the feasibility of SBT as a local treatment combination with following chemotherapy and consolidation external radiotherapy for a new try. Consolidation external radiotherapy was performed with a much lower dose than the other two patients which may also reduce the related neurotoxicity of radiation. This kind of comprehensive treatment may be a new concept to treat PCNSL and other CNS tumours with higher efficiency and lower toxicity. Such an approach will be the basis for further study.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>We believe that modified R-IDARAM consolidated with radiotherapy may improve disease control and outcome of patients. A comprehensive treatment combining SBT, modified R-IDARAM and followed reduced external radiotherapy may be a novel multimodal treatment concept to treating PCNSL with higher efficiency and lower toxicity which is valuable for multicentre clinical trials to investigate in the future.</p>
    </sec>
  </body>
  <back>
    <ack>
      <p>This work was supported by a grant from the National Natural Science Foundation of China (grant no. 81072241).</p>
    </ack>
    <sec>
      <title>Conflicts of interest</title>
      <p>The authors confirm that there are no conflicts of interest.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="b1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gerstner</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Batchelor</surname>
              <given-names>TT</given-names>
            </name>
          </person-group>
          <article-title>Primary central nervous system lymphoma</article-title>
          <source>Arch Neurol</source>
          <year>2010</year>
          <volume>67</volume>
          <fpage>291</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="pmid">20212226</pub-id>
        </element-citation>
      </ref>
      <ref id="b2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreton</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Morgan</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Gilson</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen</article-title>
          <source>Cancer Chemother Pharmacol</source>
          <year>2004</year>
          <volume>53</volume>
          <fpage>324</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">14704830</pub-id>
        </element-citation>
      </ref>
      <ref id="b3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Miller</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Hochberg</surname>
              <given-names>FH</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958&#x2013;1989</article-title>
          <source>Cancer</source>
          <year>1994</year>
          <volume>74</volume>
          <fpage>1383</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="pmid">8055462</pub-id>
        </element-citation>
      </ref>
      <ref id="b4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jahnke</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Thiel</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schilling</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Low-grade primary central nervous system lymphoma in immunocompetent patients</article-title>
          <source>Br J Haematol</source>
          <year>2005</year>
          <volume>128</volume>
          <fpage>616</fpage>
          <lpage>24</lpage>
          <pub-id pub-id-type="pmid">15725082</pub-id>
        </element-citation>
      </ref>
      <ref id="b5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Glass</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gruber</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Cher</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome</article-title>
          <source>J Neurosurg</source>
          <year>1994</year>
          <volume>81</volume>
          <fpage>188</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="pmid">8027800</pub-id>
        </element-citation>
      </ref>
      <ref id="b6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abrey</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>DeAngelis</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Yahalom</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Long-term survival in primary CNS lymphoma</article-title>
          <source>J Clin Oncol</source>
          <year>1998</year>
          <volume>16</volume>
          <fpage>859</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="pmid">9508166</pub-id>
        </element-citation>
      </ref>
      <ref id="b7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ferreri</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Reni</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dell'Oro</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients</article-title>
          <source>Oncology</source>
          <year>2001</year>
          <volume>60</volume>
          <fpage>134</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">11244328</pub-id>
        </element-citation>
      </ref>
      <ref id="b8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Abrey</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Batchelor</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Ferreri</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>5034</fpage>
          <lpage>43</lpage>
          <pub-id pub-id-type="pmid">15955902</pub-id>
        </element-citation>
      </ref>
      <ref id="b9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruge</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Kickingereder</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Grau</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region</article-title>
          <source>Neuro Oncol</source>
          <year>2013</year>
          <volume>15</volume>
          <fpage>1721</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">24046261</pub-id>
        </element-citation>
      </ref>
      <ref id="b10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Krema</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Heydarian</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Beiki-Ardakani</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dosimetric and late radiation toxicity comparison between iodine-125 brachytherapy and stereotactic radiation therapy for juxtapapillary choroidal melanoma</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>2013</year>
          <volume>86</volume>
          <fpage>510</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">23507292</pub-id>
        </element-citation>
      </ref>
      <ref id="b11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Apuzzo</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Petrovich</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Luxton</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Interstitial radiobrachytherapy of malignant cerebral neoplasms: rationale, methodology, prospects</article-title>
          <source>Neurol Res</source>
          <year>1987</year>
          <volume>9</volume>
          <fpage>91</fpage>
          <lpage>100</lpage>
          <pub-id pub-id-type="pmid">2886948</pub-id>
        </element-citation>
      </ref>
      <ref id="b12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Stereotactic biopsy for intracranial space-occupying lesions: clinical analysis of 550 cases</article-title>
          <source>Stereotact Funct Neurosurg</source>
          <year>2000</year>
          <volume>75</volume>
          <fpage>103</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">11740177</pub-id>
        </element-citation>
      </ref>
      <ref id="b13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CT-guided stereotactic biopsy of deep brain lesions: report of 310 cases</article-title>
          <source>Chin Med</source>
          <year>1998</year>
          <volume>111</volume>
          <fpage>361</fpage>
          <lpage>3</lpage>
        </element-citation>
      </ref>
      <ref id="b14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sun</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Stereotactic radiosurgery for trigeminal schwannoma: a clinical retrospective study in 52 cases</article-title>
          <source>Stereotact Funct Neurosurg</source>
          <year>2013</year>
          <volume>91</volume>
          <fpage>236</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">23548989</pub-id>
        </element-citation>
      </ref>
      <ref id="b15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Qian</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Stereotactic radiosurgery to treat presumed Rathke's cleft cysts</article-title>
          <source>Br J Neurosurg</source>
          <year>2012</year>
          <volume>26</volume>
          <fpage>684</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">22463721</pub-id>
        </element-citation>
      </ref>
      <ref id="b16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oken</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Creech</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Tormey</surname>
              <given-names>DC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Toxicity and response criteria of the Eastern Cooperative Oncology Group</article-title>
          <source>Am J Clin Oncol</source>
          <year>1982</year>
          <volume>5</volume>
          <fpage>649</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="pmid">7165009</pub-id>
        </element-citation>
      </ref>
      <ref id="b17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harris</surname>
              <given-names>NL</given-names>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Diebold</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997</article-title>
          <source>Histopathology</source>
          <year>2000</year>
          <volume>36</volume>
          <fpage>69</fpage>
          <lpage>86</lpage>
          <pub-id pub-id-type="pmid">10632755</pub-id>
        </element-citation>
      </ref>
      <ref id="b18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shah</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Yahalom</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Correa</surname>
              <given-names>DD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma</article-title>
          <source>J Clin Oncol</source>
          <year>2007</year>
          <volume>25</volume>
          <fpage>4730</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">17947720</pub-id>
        </element-citation>
      </ref>
      <ref id="b19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Poortmans</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Kluin-Nelemans</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Haaxma-Reiche</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962</article-title>
          <source>J Clin Oncol</source>
          <year>2003</year>
          <volume>21</volume>
          <fpage>4483</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">14597741</pub-id>
        </element-citation>
      </ref>
      <ref id="b20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bessell</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Graus</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lopez-Guillermo</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>2001</year>
          <volume>50</volume>
          <fpage>457</fpage>
          <lpage>64</lpage>
          <pub-id pub-id-type="pmid">11380234</pub-id>
        </element-citation>
      </ref>
      <ref id="b21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yilmaz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Erkutlu</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Kilciksiz</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases</article-title>
          <source>Hematology</source>
          <year>2008</year>
          <volume>13</volume>
          <fpage>107</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">18616878</pub-id>
        </element-citation>
      </ref>
      <ref id="b22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Donehower</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Karp</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion</article-title>
          <source>Cancer Treat Rep</source>
          <year>1986</year>
          <volume>70</volume>
          <fpage>1059</fpage>
          <lpage>65</lpage>
          <pub-id pub-id-type="pmid">3461882</pub-id>
        </element-citation>
      </ref>
      <ref id="b23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reid</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Pendergrass</surname>
              <given-names>TW</given-names>
            </name>
            <name>
              <surname>Krailo</surname>
              <given-names>MD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report</article-title>
          <source>Cancer Res</source>
          <year>1990</year>
          <volume>50</volume>
          <fpage>6525</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">2208112</pub-id>
        </element-citation>
      </ref>
      <ref id="b24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walker</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Hilton</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Nitrosourea pharmacodynamics in relation to the central nervous system</article-title>
          <source>Cancer Treat Rep</source>
          <year>1976</year>
          <volume>60</volume>
          <fpage>725</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">954011</pub-id>
        </element-citation>
      </ref>
      <ref id="b25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rubenstein</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Combs</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rosenberg</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>101</volume>
          <fpage>466</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">12393404</pub-id>
        </element-citation>
      </ref>
      <ref id="b26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stewart</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Endothelial vesicles in the blood-brain barrier: are they related to permeability?</article-title>
          <source>Cell Mol Neurobiol</source>
          <year>2000</year>
          <volume>20</volume>
          <fpage>149</fpage>
          <lpage>63</lpage>
          <pub-id pub-id-type="pmid">10696507</pub-id>
        </element-citation>
      </ref>
      <ref id="b27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Brien</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Roos</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Pratt</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma</article-title>
          <source>J Clin Oncol</source>
          <year>2000</year>
          <volume>18</volume>
          <fpage>519</fpage>
          <lpage>26</lpage>
          <pub-id pub-id-type="pmid">10653867</pub-id>
        </element-citation>
      </ref>
      <ref id="b28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shibamoto</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ogino</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hasegawa</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>2005</year>
          <volume>62</volume>
          <fpage>809</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">15936564</pub-id>
        </element-citation>
      </ref>
      <ref id="b29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DeAngelis</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Seiferheld</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schold</surname>
              <given-names>SC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10</article-title>
          <source>J Clin Oncol</source>
          <year>2002</year>
          <volume>20</volume>
          <fpage>4643</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">12488408</pub-id>
        </element-citation>
      </ref>
      <ref id="b30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fitzsimmons</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Upchurch</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Batchelor</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Clinical features and diagnosis of primary central nervous system lymphoma</article-title>
          <source>Hematol Oncol Clin North Am</source>
          <year>2005</year>
          <volume>19</volume>
          <fpage>689</fpage>
          <lpage>703</lpage>
          <pub-id pub-id-type="pmid">16083830</pub-id>
        </element-citation>
      </ref>
      <ref id="b31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwarz</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Thon</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nikolajek</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Iodine-125 brachytherapy for brain tumours&#x2013;a review</article-title>
          <source>Radiat Oncol</source>
          <year>2012</year>
          <volume>7</volume>
          <fpage>30</fpage>
          <pub-id pub-id-type="pmid">22394548</pub-id>
        </element-citation>
      </ref>
      <ref id="b32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruge</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Kickingereder</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome</article-title>
          <source>J Neurooncol</source>
          <year>2012</year>
          <volume>109</volume>
          <fpage>273</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="pmid">22580799</pub-id>
        </element-citation>
      </ref>
      <ref id="b33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ruge</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Simon</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Suchorska</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome</article-title>
          <source>J Clin Oncol</source>
          <year>2011</year>
          <volume>29</volume>
          <fpage>4151</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">21969508</pub-id>
        </element-citation>
      </ref>
      <ref id="b34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kreth</surname>
              <given-names>FW</given-names>
            </name>
            <name>
              <surname>Thon</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Siefert</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The place of interstitial brachytherapy and radiosurgery for low-grade gliomas</article-title>
          <source>Adv Tech Stand Neurosurg</source>
          <year>2010</year>
          <volume>35</volume>
          <fpage>183</fpage>
          <lpage>212</lpage>
          <pub-id pub-id-type="pmid">20102115</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
